cobaltous chloride has been researched along with bosentan anhydrous in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belhaj, A; Dewachter, C; Dewachter, L; Maruyama, H; Naeije, R; Remmelink, M; Rondelet, B; Sakai, S; Vachiéry, JL | 1 |
1 other study(ies) available for cobaltous chloride and bosentan anhydrous
| Article | Year |
|---|---|
Bosentan reverses the hypoxia-induced downregulation of the bone morphogenetic protein signaling in pulmonary artery smooth muscle cells.
Topics: Bone Morphogenetic Proteins; Bosentan; Cells, Cultured; Cobalt; Down-Regulation; Endothelin Receptor Antagonists; Humans; Hypoxia; Muscle, Smooth, Vascular; Pulmonary Artery; Signal Transduction; Sulfonamides | 2016 |